Alice Shaw
Co-Leader, Lung Cancer Program, Dana Farber/Harvard Cancer Center · New York Presbyterian Hospital
Credentials: · · · ·
History
PresentLung Cancer Program · New York Presbyterian Hospital
- 1995–1999
Research
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
New England Journal of Medicine · 2010 · 3,649 citations
Tumour heterogeneity and resistance to cancer therapies
Review · Nature Reviews Clinical Oncology · 2018 · 2,899 citations
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
Science Translational Medicine · 2011 · 2,891 citations
- JG
73 papers · 12 as a fellow
- JE
42 papers
41 papers
- ID
40 papers · 20 as a fellow
36 papers
- MM
33 papers
- SD
33 papers
- SO
32 papers
Grants
- 2022–2027
Dana Farber/Harvard Cancer Center SPORE in Lung Cancer
National Cancer Institute · P50
Project lead · $1M · Dana-Farber Cancer Inst
- 1997–2023
Training Program in Cancer Biology and Therapeutics
National Cancer Institute · T32
PI · $685.5K · Massachusetts General Hospital
- 2012–2022
Overcoming Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors
National Cancer Institute · R01
Contact PI · $2.7M · Massachusetts General Hospital
- 2005–2010
Ras Signaling in Development and Cancer
National Cancer Institute · K08
Contact PI · $679.8K · Massachusetts General Hospital
Clinical trials
- 2017–2019
Principal investigator · Completed · Phase 2
Massachusetts General Hospital
- 2013–2017
AUY922 for Advanced ALK-positive NSCLC
Principal investigator · Completed · Phase 2
Massachusetts General Hospital
- 2026–2034
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
Site PI · Recruiting · Phase 1, Phase 2
TRIANA Biomedicines, Inc.
- 2025–2029
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Site PI · Recruiting · Phase 3
Nuvalent Inc.